Amneal Pharmaceuticals (AMRX) Notes Payables (2017 - 2024)

Amneal Pharmaceuticals has reported Notes Payables for 8 years, with the latest figure at $31.4 million in Q2 2024.

• On a quarterly basis, Notes Payables changed N/A year-over-year to $31.4 million in Q2 2024; TTM through Jun 2024 was $31.4 million, a N/A change from a year earlier, with the FY2022 full-year figure at $2.5 million, down 94.82% from the prior year.
• Notes Payables was $31.4 million for Q2 2024 at Amneal Pharmaceuticals, up from $14.8 million in the prior quarter.
• The five-year high for Notes Payables was $47.9 million in Q4 2021, with the low at $2.5 million in Q4 2022.
• Average Notes Payables over 5 years is $18.7 million, with a median of $15.4 million recorded in 2022.
• The sharpest annual moves came in 2020 and 2022: Notes Payables surged 954.77% in 2020, then slumped 94.82% in 2022.
• Over 5 years, Notes Payables stood at $7.6 million in 2020, then soared by 533.0% to $47.9 million in 2021, then plunged by 94.82% to $2.5 million in 2022, then soared by 495.0% to $14.8 million in 2023, then soared by 112.63% to $31.4 million in 2024.
• The last three Notes Payables figures came in at $31.4 million (Q2 2024), $14.8 million (Q1 2023), and $2.5 million (Q4 2022), per Business Quant data.